187 related articles for article (PubMed ID: 8822271)
1. Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors.
de Winter JP; ten Dijke P; de Vries CJ; van Achterberg TA; Sugino H; de Waele P; Huylebroeck D; Verschueren K; van den Eijnden-van Raaij AJ
Mol Cell Endocrinol; 1996 Jan; 116(1):105-14. PubMed ID: 8822271
[TBL] [Abstract][Full Text] [Related]
2. Truncated activin type II receptors inhibit bioactivity by the formation of heteromeric complexes with activin type I. receptors.
De Winter JP; De Vries CJ; Van Achterberg TA; Ameerun RF; Feijen A; Sugino H; De Waele P; Huylebroeck D; Verschueren K; Van Den Eijden-Van Raaij AJ
Exp Cell Res; 1996 May; 224(2):323-34. PubMed ID: 8612709
[TBL] [Abstract][Full Text] [Related]
3. A novel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate.
Hashimoto O; Nakamura T; Shoji H; Shimasaki S; Hayashi Y; Sugino H
J Biol Chem; 1997 May; 272(21):13835-42. PubMed ID: 9153241
[TBL] [Abstract][Full Text] [Related]
4. Difference between follistatin isoforms in the inhibition of activin signalling: activin neutralizing activity of follistatin isoforms is dependent on their affinity for activin.
Hashimoto O; Kawasaki N; Tsuchida K; Shimasaki S; Hayakawa T; Sugino H
Cell Signal; 2000 Aug; 12(8):565-71. PubMed ID: 11027950
[TBL] [Abstract][Full Text] [Related]
5. Molecular heterogeneity of follistatin, an activin-binding protein. Higher affinity of the carboxyl-terminal truncated forms for heparan sulfate proteoglycans on the ovarian granulosa cell.
Sugino K; Kurosawa N; Nakamura T; Takio K; Shimasaki S; Ling N; Titani K; Sugino H
J Biol Chem; 1993 Jul; 268(21):15579-87. PubMed ID: 8340384
[TBL] [Abstract][Full Text] [Related]
6. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation.
Di Simone N; Crowley WF; Wang QF; Sluss PM; Schneyer AL
Endocrinology; 1996 Feb; 137(2):486-94. PubMed ID: 8593793
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of binding proteins for inhibin and activin in human serum and follicular fluids.
Krummen LA; Woodruff TK; DeGuzman G; Cox ET; Baly DL; Mann E; Garg S; Wong WL; Cossum P; Mather JP
Endocrinology; 1993 Jan; 132(1):431-43. PubMed ID: 7678220
[TBL] [Abstract][Full Text] [Related]
8. Follistatin and its role as an activin-binding protein.
Sugino H; Sugino K; Hashimoto O; Shoji H; Nakamura T
J Med Invest; 1997 Aug; 44(1-2):1-14. PubMed ID: 9395712
[TBL] [Abstract][Full Text] [Related]
9. A two-site chemiluminescent assay for activin-free follistatin reveals that most follistatin circulating in men and normal cycling women is in an activin-bound state.
McConnell DS; Wang Q; Sluss PM; Bolf N; Khoury RH; Schneyer AL; Midgley AR; Reame NE; Crowley WF; Padmanabhan V
J Clin Endocrinol Metab; 1998 Mar; 83(3):851-8. PubMed ID: 9506739
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of native activin B.
Nakamura T; Asashima M; Eto Y; Takio K; Uchiyama H; Moriya N; Ariizumi T; Yashiro T; Sugino K; Titani K
J Biol Chem; 1992 Aug; 267(23):16385-9. PubMed ID: 1644823
[TBL] [Abstract][Full Text] [Related]
11. Inhibins, activins, and follistatins: expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia.
Thomas TZ; Chapman SM; Hong W; Gurusingfhe C; Mellor SL; Fletcher R; Pedersen J; Risbridger GP
Prostate; 1998 Jan; 34(1):34-43. PubMed ID: 9428386
[TBL] [Abstract][Full Text] [Related]
12. Follistatin-activin complexes in human serum and follicular fluid differ immunologically and biochemically.
Schneyer AL; Hall HA; Lambert-Messerlian G; Wang QF; Sluss P; Crowley WF
Endocrinology; 1996 Jan; 137(1):240-7. PubMed ID: 8536619
[TBL] [Abstract][Full Text] [Related]
13. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.
Yamashita H; ten Dijke P; Huylebroeck D; Sampath TK; Andries M; Smith JC; Heldin CH; Miyazono K
J Cell Biol; 1995 Jul; 130(1):217-26. PubMed ID: 7790373
[TBL] [Abstract][Full Text] [Related]
14. Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin.
Sidis Y; Tortoriello DV; Holmes WE; Pan Y; Keutmann HT; Schneyer AL
Endocrinology; 2002 May; 143(5):1613-24. PubMed ID: 11956142
[TBL] [Abstract][Full Text] [Related]
15. Pituitary activin receptor subtypes and follistatin gene expression in female rats: differential regulation by activin and follistatin.
Dalkin AC; Haisenleder DJ; Yasin M; Gilrain JT; Marshall JC
Endocrinology; 1996 Feb; 137(2):548-54. PubMed ID: 8593801
[TBL] [Abstract][Full Text] [Related]
16. Identification of activins and follistatin proteins in human follicular fluid and placenta.
Yokoyama Y; Nakamura T; Nakamura R; Irahara M; Aono T; Sugino H
J Clin Endocrinol Metab; 1995 Mar; 80(3):915-21. PubMed ID: 7883850
[TBL] [Abstract][Full Text] [Related]
17. Tissue-specific binding of radiolabeled activin A by activin receptors and follistatin in postimplantation rat and mouse embryos.
Roberts VJ; Bentley CA; Guo Q; Matzuk MM; Woodruff TK
Endocrinology; 1996 Oct; 137(10):4201-9. PubMed ID: 8828478
[TBL] [Abstract][Full Text] [Related]
18. Activin and follistatin as local regulators in the human ovary.
Peng C; Ohno T; Khorasheh S; Leung PC
Biol Signals; 1996; 5(2):81-9. PubMed ID: 8836491
[TBL] [Abstract][Full Text] [Related]
19. Cell survival effect of activin against heat shock stress on OVCAR3.
Fukuda J; Ito I; Tanaka T; Leung PC
Life Sci; 1998; 63(25):2209-20. PubMed ID: 9870706
[TBL] [Abstract][Full Text] [Related]
20. Activin A in JEG-3 cells: potential role as an autocrine regulator of steroidogenesis in humans.
Ni X; Luo S; Minegishi T; Peng C
Biol Reprod; 2000 May; 62(5):1224-30. PubMed ID: 10775170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
